






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Triple Combination Therapy in High Risk Crohn&apos;s Disease - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT02764762" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="861650e698601876_927f1SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT02764762"/>
  <meta name="ncbi_ctreqid" content="RRe02WKj"/>
  <meta name="ncbi_ctsessid" content="SRe01hyp"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp2"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Triple Combination Therapy in High Risk Crohn's Disease</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div class="recruiting-status">
      This study is currently recruiting participants.
                  <div style="margin-top:1ex;text-align:center;">
	           <font color=black>See </font><a href="/ct2/show/study/NCT02764762#contacts"><img src="/ct2/html/images/frame/triangle.gif" style="width:1em;" alt=""/>
	           <span class="header2" style="font-size:inherit;"> Contacts and Locations</span></a>
	        </div>
          </div>
        
        
        <div  class="status-details" 
title="The verification date is the most recent date the responsible party verified the study information is correct.  The last updated date is the most recent date the record changed in any way.  The two dates may be different.">
      <span style="color:#0000cc">Verified April 2017</span> by Takeda
    </div>
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> Takeda </div>



                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">Takeda</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT02764762</div>
                <div class="info-date">First received: May 5, 2016</div>
                <div class="info-date">Last updated:  April 6, 2017</div>
                <div class="info-date">Last verified:  April 2017 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT02764762"
          title="Historical versions of study NCT02764762 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT02764762'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT02764762"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT02764762">No Study Results Posted</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">May 5, 2016</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">April 6, 2017</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Actual Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">April 5, 2017</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Primary Completion Date </th>
            <td class="body3 rowBody">April 23, 2021 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;February 16, 2017)</span></th>
            <td class="body3 rowBody">Percentage of Participants Achieving Endoscopic Remission at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic remission is defined as simple endoscopic score for Crohn&apos;s Disease (SES-CD) scale score from 0-2. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;May 5, 2016)</span></th>
            <td class="body3 rowBody">Percentage of Participants Achieving Endoscopic Remission at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic remission is defined as simple endoscopic score for Crohn&apos;s Disease (SES-CD) scale score from 0-2. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT02764762" onclick="openNewWindow('/ct2/archive/NCT02764762'); return false;">Complete list of historical versions of study NCT02764762 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;February 16, 2017)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Endoscopic Healing at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic healing is defined as SES-CD score &#8804;4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore &gt;1. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Endoscopic Response at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic response is defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in SES-CD Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Deep Remission at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Deep remission is defined as Crohn&apos;s disease activity index (CDAI) score&lt;150 and SES-CD score from 0-2. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Response at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical response is defined as &#8805;100-point decrease in CDAI score. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in C-Reactive Protein (CRP) Levels at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The change between the CRP levels collected at Weeks 10 and 26 relative to Baseline.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 26, 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 10, 26, 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">The change between the fecal calprotectin concentrations collected at Weeks 10, 26, 52, 78, and 102 relative to Baseline.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission and CRP &lt;5 mg/L at Weeks 26, 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 26, 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150 and CRP level &lt;5 mg/L in participants with elevated CRP level at Baseline. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Using Oral Corticosteroids at Baseline who Have Discontinued Corticosteroids and are in Clinical Remission at Weeks 10, 26, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10, 26 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Percentage of participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission at weeks 10, 26, and 102 will be reported. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Remission at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic remission is defined as SES-CD score 0-2. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Deep Remission at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Deep remission is defined as CDAI score &lt;150 and SES-CD score 0-2. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Healing at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic healing is defined as SES-CD score &#8804;4 and reduction from Baseline in SES-CD score of at least 2 points and no individual SES-CD subscore &gt;1. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Response at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic response is defined as 50% reduction in SES-CD score from Baseline. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Endoscopic response defined as 50% reduction in SES-CD score from Baseline, as mucosal healing. CDAI is scoring system for assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With First Exacerbation of Crohn&apos;s disease (CD) [&nbsp;Time&nbsp;Frame:&nbsp;After 26 Weeks up to Week 128&nbsp;]<div class="indent2" style="margin-top:1ex;">First exacerbation of CD after 26 weeks is defined as either: 1) a CDAI increase of &gt;70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal OR 2) fecal calprotectin &gt;250 &#956;g/gm. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;May 5, 2016)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Endoscopic Healing at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic healing is defined as SES-CD score &#8804;4 and reduction from baseline in SES-CD score of at least 2 points and no individual SES-CD subscore &gt;1. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Endoscopic Response at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic response is defined as 50% reduction in SES-CD score from baseline. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in SES-CD Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline and Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Deep Remission at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Deep remission is defined as Crohn&apos;s disease activity index (CDAI) score&lt;150 and SES-CD score from 0-2. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Endoscopic response defined as 50% reduction in SES-CD score from baseline, as mucosal healing. CDAI is scoring system for assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Response at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical response is defined as &#8805;100-point decrease in CDAI score. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in C-Reactive Protein (CRP) Levels at Weeks 10 and 26 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 10 and 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The change between the CRP levels collected at Weeks 10 and 26 relative to Baseline.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in Fecal Calprotectin Concentrations at Weeks 10, 26, 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Weeks 10, 26, 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">The change between the fecal calprotectin concentrations collected at Weeks 10, 26, 52, 78, and 102 relative to Baseline.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Achieving Clinical Remission and CRP &lt;5 mg/L at Weeks 26, 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 26, 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150 and CRP level &lt;5 mg/L in participants with elevated CRP level at Baseline. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Using Oral Corticosteroids at Baseline who Have Discontinued Corticosteroids and are in Clinical Remission at Weeks 10, 26, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 10, 26 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Percentage of participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission at weeks 10, 26, and 102 will be reported. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Clinical Remission at Weeks 52, 78, and 102 [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 52, 78 and 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Remission at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic remission is defined as SES-CD score 0-2. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Deep Remission at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Deep remission is defined as CDAI score &lt;150 and SES-CD score 0-2. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Healing at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic healing is defined as SES-CD score &#8804;4 and reduction from baseline in SES-CD score of at least 2 points and no individual SES-CD subscore &gt;1. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Endoscopic Response at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Endoscopic response is defined as 50% reduction in SES-CD score from baseline. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants Maintaining Clinical Remission and Endoscopic Response as a Measure of Mucosal Healing at Week 102 [&nbsp;Time&nbsp;Frame:&nbsp;Week 102&nbsp;]<div class="indent2" style="margin-top:1ex;">Clinical remission is defined as CDAI score &lt;150. Endoscopic response defined as 50% reduction in SES-CD score from baseline, as mucosal healing. CDAI is scoring system for assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease. The SES-CD evaluates 4 endoscopic variables (ulcer size, proportion of the surface area that is ulcerated, proportion of the surface area affected, and stenosis in 5 segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). The SES-CD total is sum of the 4 endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Participants With First Exacerbation of Crohn&apos;s disease (CD) [&nbsp;Time&nbsp;Frame:&nbsp;After 26 Weeks up to Week 128&nbsp;]<div class="indent2" style="margin-top:1ex;">First exacerbation of CD is defined as a CDAI increase of &gt;70 from the prior visit on 2 occasions separated by a 2-week interval, objective evidence of disease activity by colonoscopy or CRP above normal or fecal calprotectin &gt;250 &#956;g/gm. Clinical remission is defined as CDAI score &lt;150. CDAI is scoring system for the assessment of Crohn&apos;s Disease Activity, index values of 150 and below are associated with quiescent disease; values above that indicate active disease and values above 450 are seen with extremely severe disease.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Triple Combination Therapy in High Risk Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin [vedolizumab intravenous (IV)], a tumor necrosis factor (TNF) antagonist [adalimumab subcutaneously (SC)], and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed Crohn's disease stratified at higher risk for complications.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have Crohn's Disease. This study will look at the endoscopic remission and mucosal healing of gastrointestinal tract of people who take vedolizumab as triple combination therapy with adalimumab and methotrexate.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The study will enroll approximately 60 patients. Participants will receive triple combination therapy which includes:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Vedolizumab 300 mg</li>
    <li style="margin-top:0.7ex;">Adalimumab 160/80/40 mg</li>
    <li style="margin-top:0.7ex;">Methotrexate 15 mg</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">All participants will receive vedolizumab IV infusion on Weeks 0, 2, 6, 14 and 22 along with adalimumab 160 mg, SC injection at Week 0, 80 mg at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with methotrexate tablets orally, once weekly from Weeks 0 up to Week 34. In monotherapy phase, all participants will receive vedolizumab IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">This multi-center trial will be conducted in United States and Canada. The overall time to participate in this study is 128 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a safety follow-up assessment. Participants will also participate in a long-term safety questionnaire, by phone, at 18 weeks and 26 weeks (6 months) from the last dose of study drug.</p></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 4</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Intervention Model: Single Group Assignment<br/>Masking: Participant, Care Provider, Investigator, Outcomes Assessor<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Crohn Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Drug: Vedolizumab
<div class="indent2" style="margin-top:0.5ex">Vedolizumab IV infusion</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Entyvio</li>
<li>MLN0002 IV</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Drug: Adalimumab
<div class="indent2" style="margin-top:0.5ex">Adalimumab SC injection</div></li>
<li style="margin:1ex 0.5ex">Drug: Methotrexate
<div class="indent2" style="margin-top:0.5ex">Methotrexate Tablets</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody">Experimental: Vedolizumab 300 mg+Adalimumab 160-40 mg+Methotrexate 15 mg
<div class="indent2" style="margin-top:0.5ex">In Triple Combination Therapy Phase, vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2, 6, 14 and 22, along with adalimumab 160 mg subcutaneously (SC), once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34. In Monotherapy Phase, vedolizumab 300 mg IV infusion once at Weeks 30, 38, 46, 54, 62, 70, 78, 86, 94 and 102.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Drug: Vedolizumab</li>
<li>Drug: Adalimumab</li>
<li>Drug: Methotrexate</li>
</ul>
</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Recruiting</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">60</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Completion Date </th>
            <td class="body3 rowBody">April 23, 2021</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Estimated Primary Completion Date </th>
            <td class="body3 rowBody">April 23, 2021 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.</li>
    <li style="margin-top:0.7ex;">The participant or, when applicable, the participant's legally acceptable representative has signed and dated a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.</li>
    <li style="margin-top:0.7ex;">Is male or non-pregnant, non-breast-feeding female and aged 18 to 80 years, inclusive at time of Screening.</li>
    <li style="margin-top:0.7ex;">Has an initial diagnosis of Crohn's disease (CD) established within 24 months prior to enrollment with involvement of the ileum and/or colon that can be assessed by ileocolonoscopy.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has moderate to severely active CD during Screening defined by:</p>
      <ol style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Crohn's disease activity index (CDAI) score &#8805; 220 within 10 days prior to enrollment, AND</li>
        <li style="margin-top:0.7ex;">Centrally assessed simple endoscopic score for Crohn's disease (SES-CD) score &#8805;7 (or &#8805;4 if isolated ileal disease) during Screening, AND</li>
        <li style="margin-top:0.7ex;">Elevated biomarker of inflammation [C-reactive protein (CRP) &gt;5 mg/L OR fecal calprotectin level &gt;250 &#956;g/g stool) during Screening.</li>
      </ol>
    </li>
    <li style="margin-top:0.7ex;">By investigator judgement, the participant is assessed as having CD at moderate-high risk for complications. Investigator judgement may include clinical assessment, the Crohn's Disease Personalized Risk and Outcome Prediction Tool (PROSPECT), or criteria defined by the 2014 American Gastroenterology Association (AGA) CD Clinical Care Pathway.</li>
    <li style="margin-top:0.7ex;">May be receiving a stable therapeutic dose of conventional therapies for CD.</li>
    <li style="margin-top:0.7ex;">If on corticosteroids, must be on a stable dose of oral corticosteroids up to 20 mg of prednisone daily or 9 mg of budesonide daily for at least 7 days prior to enrollment.</li>
    <li style="margin-top:0.7ex;">If on corticosteroids, must be willing to follow a mandatory taper of prednisone or budesonide within 60 days after enrollment.</li>
    <li style="margin-top:0.7ex;">Must be willing to stop treatment with 5-aminosalicylate (5-ASA), antibiotics, and probiotics for luminal CD at enrollment.</li>
    <li style="margin-top:0.7ex;">Male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.</li>
    <li style="margin-top:0.7ex;">Female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.</li>
    <li style="margin-top:0.7ex;">Family history of colorectal cancer, personal history of increased colorectal cancer risk, age &gt;50 years, or other known risk factors must be up-to-date on colorectal cancer surveillance (may be performed during Screening as standard of care).</li>
  </ol>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Gastrointestinal (GI) Exclusion Criteria</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Has a diagnosis of ulcerative colitis (UC) or indeterminate colitis.</li>
    <li style="margin-top:0.7ex;">Has clinical evidence of a current abdominal abscess or a history of prior abdominal abscess.</li>
    <li style="margin-top:0.7ex;">Has a known perianal fistula with abscess. (The participant may have a perianal fistula without abscess.)</li>
    <li style="margin-top:0.7ex;">Has a known fistula (other than perianal fistula).</li>
    <li style="margin-top:0.7ex;">Had non-CD related abdominal surgery within 6 months prior to enrollment.</li>
    <li style="margin-top:0.7ex;">Has any prior CD-related surgery OR CD complication requiring surgery at any time (other than seton placement for perianal fistula without abscess).</li>
    <li style="margin-top:0.7ex;">Has a history of 2 or more non CD related small bowel resections or diagnosis of short bowel syndrome.</li>
    <li style="margin-top:0.7ex;">Has extensive non CD related colonic resection, ie, subtotal or total colectomy with &lt;15 cm colon remaining.</li>
    <li style="margin-top:0.7ex;">Has an ileostomy, colostomy.</li>
    <li style="margin-top:0.7ex;">Has a history or evidence of adenomatous colonic polyps that have not been removed.</li>
    <li style="margin-top:0.7ex;">Has a history or evidence of colonic mucosal dysplasia.</li>
    <li style="margin-top:0.7ex;">Has intolerance or contraindication to undergo ileocolonoscopy.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has known fixed stricture or stenosis of the intestine.</p>
      <p style="margin-top:0ex; margin-bottom:1ex;">Infectious Disease Exclusion Criteria</p>
    </li>
    <li style="margin-top:0.7ex;">Has any identified congenital or acquired immunodeficiency [eg, common variable immunodeficiency, human immunodeficiency virus (HIV) infection].</li>
    <li style="margin-top:0.7ex;">Has undergone organ transplantation.</li>
    <li style="margin-top:0.7ex;">Has evidence of an active infection during Screening.</li>
    <li style="margin-top:0.7ex;">Infections requiring treatment with oral (PO) or intravenous (IV) antibiotics, antivirals, or antifungals within 28 days of enrollment.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:</p>
      <ol style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">History of TB.</li>
        <li style="margin-top:0.7ex;">
          <p style="margin-top:0ex; margin-bottom:1ex;">A diagnostic TB test performed during Screening that is positive, as defined by:</p>
          <p style="margin-top:0ex; margin-bottom:1ex;">&#8226; A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests OR</p>
        </li>
        <li style="margin-top:0.7ex;">A tuberculin skin test reaction &#8805;10 mm (&#8805;5 mm in participants receiving the equivalent of &gt;15 mg/day prednisone)</li>
      </ol>
    </li>
    <li style="margin-top:0.7ex;">Has a history of listeria, histoplasmosis, coccidioidomycosis, blastomycosis, candidiasis, aspergillosis, legionella, or pneumocystosis.</li>
    <li style="margin-top:0.7ex;">Has a history of any bacterial, viral, and other infection due to opportunistic pathogens.</li>
    <li style="margin-top:0.7ex;">Has chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.</li>
    <li style="margin-top:0.7ex;">Has evidence of active Clostridium difficile infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has received any live vaccinations within 28 days prior to enrollment.</p>
      <p style="margin-top:0ex; margin-bottom:1ex;">General Exclusion Criteria</p>
    </li>
    <li style="margin-top:0.7ex;">Has other inflammatory or rheumatic diseases (eg, psoriasis, rheumatoid arthritis, ankylosing spondylitis).</li>
    <li style="margin-top:0.7ex;">Had a surgical procedure requiring general anesthesia within 60 days prior to enrollment or is planning to undergo major surgery during the study period.</li>
    <li style="margin-top:0.7ex;">Is taking, has taken, or is required to take any excluded medications.</li>
    <li style="margin-top:0.7ex;">Has received either approved or investigational biologic or nonbiologic agents for the treatment of inflammatory bowel disease (IBD) in an investigational protocol.</li>
    <li style="margin-top:0.7ex;">Has had prior exposure to any tumor necrosis factor (TNF) antagonist including infliximab, certolizumab pegol, golimumab, adalimumab, or biosimilar TNF antagonist agents.</li>
    <li style="margin-top:0.7ex;">Has had prior exposure to vedolizumab, natalizumab, efalizumab, or rituximab.</li>
    <li style="margin-top:0.7ex;">Has received either approved or investigational biologic agents for the treatment of non-inflammatory bowel disease (IBD) conditions, other than localized injections (eg, intraocular injections for wet macular degeneration).</li>
    <li style="margin-top:0.7ex;">Has a history of hypersensitivity or allergies to methotrexate, vedolizumab, adalimumab, or their components.</li>
    <li style="margin-top:0.7ex;">Has a medical history that contraindicates the use of vedolizumab, adalimumab, or methotrexate as per each drug's package insert.</li>
    <li style="margin-top:0.7ex;">Has conditions which, in the opinion of the investigator, may interfere with the participant's ability to comply with the study procedures.</li>
    <li style="margin-top:0.7ex;">Has a history of any lymphoma or lymphoproliferative disease.</li>
    <li style="margin-top:0.7ex;">Has a history of congestive heart failure (New York Heart Association class III/IV) or unstable angina.</li>
    <li style="margin-top:0.7ex;">Has renal insufficiency, ascites, pleural effusion, or underlying liver disease.</li>
    <li style="margin-top:0.7ex;">Has any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, GI, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurologic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise participant safety.</li>
    <li style="margin-top:0.7ex;">Has had gastric bypass surgery.</li>
    <li style="margin-top:0.7ex;">Has symptoms of shortness of breath and cough and/or a diagnosis of clinically significant lung disease.</li>
    <li style="margin-top:0.7ex;">Has a history of malignancy, except for the following: adequately-treated nonmetastatic basal cell skin cancer; squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to Screening; and history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to Screening. Participants with a remote history of malignancy (eg, &gt;10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received; this must be discussed with the sponsor on a case-by-case basis prior to enrollment.</li>
    <li style="margin-top:0.7ex;">Has a history of any major neurological disorders, including stroke, central nervous system demyelinating disease, brain tumor, or neurodegenerative disease.</li>
    <li style="margin-top:0.7ex;">Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist prior to the administration of study drug.</li>
    <li style="margin-top:0.7ex;">Has a history of pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia (WBC count &lt;3 &#215; 10^9/L), thrombocytopenia (platelet count &lt;100 &#215; 10/L), or significant anemia (hemoglobin level &lt;8 g/dL).</li>
    <li style="margin-top:0.7ex;">Has rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.</li>
    <li style="margin-top:0.7ex;">
      <p style="margin-top:0ex; margin-bottom:1ex;">Has any of the following laboratory abnormalities during the Screening period:</p>
      <ol style="margin-top:1ex; margin-bottom:1ex;">
        <li style="margin-top:0.7ex;">Hemoglobin level &lt;8 g/dL.</li>
        <li style="margin-top:0.7ex;">WBC count &lt;3 x 10^9/L.</li>
        <li style="margin-top:0.7ex;">Lymphocyte count &lt;0.5 x 10^9/L.</li>
        <li style="margin-top:0.7ex;">Platelet count &lt;100 x 10^9/L or &gt;1200 x 10^9/L.</li>
        <li style="margin-top:0.7ex;">Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.5 the upper limit of normal (ULN).</li>
        <li style="margin-top:0.7ex;">Alkaline phosphatase &gt;1.5 x ULN.</li>
        <li style="margin-top:0.7ex;">Renal dysfunction (serum creatinine concentration greater than 1.5 mg per deciliter [133 &#181;mol per liter]) or estimated glomerular filtration rate (eGFR) &lt;50 mL/min/1.73 m^2 at Screening Note: Retesting laboratory values during the screening interval may be considered with consultation from the Medical Monitor.</li>
      </ol>
    </li>
    <li style="margin-top:0.7ex;">Has a history of high alcohol consumption (more than 7 drinks per week), a history of prior alcohol abuse within 5 years prior to enrollment, has alcoholic liver disease, has withdrawal symptoms, or a history of illicit drug use.</li>
    <li style="margin-top:0.7ex;">Has an active psychiatric problem that, in the investigator's opinion, may interfere with compliance with study procedures.</li>
    <li style="margin-top:0.7ex;">Is unable to attend all the study visits or comply with study procedures.</li>
    <li style="margin-top:0.7ex;">Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g, spouse, parent, child, sibling) or may consent under duress.</li>
    <li style="margin-top:0.7ex;">Body mass index is &gt;35.</li>
    <li style="margin-top:0.7ex;">If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 6 months after participating in this study; or intending to donate ova during such time period.</li>
    <li style="margin-top:0.7ex;">If male, the participant intends to father a child or donate sperm during the course of this study or for 6 months thereafter.</li>
  </ol></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">18 Years to 80 Years &nbsp; (Adult, Senior)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><a name="contacts"/><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Contact: Takeda Study Registration Call Center</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">+1-877-825-3327</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;"><a href="mailto:medicalinformation%40tpna.com">medicalinformation@tpna.com</a></td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;"></td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Canada, &nbsp; United States</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3"> &nbsp; </td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT02764762</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Vedolizumab-4006<br> U1111-1175-9094 ( Registry Identifier: WHO )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Studies a U.S. FDA-regulated Drug Product:  </td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Yes</td>
  </tr>
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Studies a U.S. FDA-regulated Device Product:  </td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">No</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Medical Director Clinical Science</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">Takeda</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">Takeda</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">April 2017</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02764762" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT02764762'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
